2023-2028 Europe Molecular Diagnostics Market Opportunities--France, Germany, Italy, Spain, UK--2023 Competitor Shares and Growth Strategies, Five-Year Volume and Sales Segment Forecasts for 100 Infectious, Genetic, Cancer, Forensic and Paternity Tests--Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers

November 2023 | | ID: 2C37B5960363EN
Venture Planning Group

Abstracts

This new five-country report is designed to help current suppliers and potential market entrants identify and evaluate the major business opportunities emerging in the European molecular diagnostics market during the next five years.The report is available by section, and can be customized to specific information needs and budget. The report explores business and technological trends in major European countries (France, Germany, Italy, Spain, UK); provides 5-year test volume/sales forecasts; estimates shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.The $4.5 billion molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of and cost-effective automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostics companies during the next five years.Geographic Coverage%li%France

%li%Germany

%li%Italy

%li%Spain

%li%UKMarket Overview%li%Laboratories performing DNA sequencing and molecular diagnostic testing by country and market segment.%li%Five-year test volume and sales projections by country.Market Segmentation Analysis

• Sales and market shares of key suppliers of molecular diagnostic reagent kits and components in major markets.

Five-year test volume and sales forecasts for major applications, including:%li%Infectious Diseases%li%Forensic Testing%li%Cancer%li%Paternity Testing/HLA Typing%li%Genetic Diseases%li%Others%li%Five-year test volume and sales projections for over 30 NAT assays.%li%A comprehensive analysis of the sequencing market, by country and laboratory segment, including:%li%Industrial%li%Academic%li%Government%li%Commercial

• Market segmentation analysis, including review of the market dynamics, trends, structure, size, growth and suppliers in major countries.

Product/Technology Review

• Comparison of leading molecular diagnostic analyzers marketed by Abbott, Beckman Coulter, BD, Bio-Rad, Gen-Probe, Roche, Tecan and other suppliers.
• Extensive review of molecular diagnostic technologies, test formats, detection methodologies, trends in testing automation and over 30 target/signal amplification methods.
• Universities and research centers developing new molecular diagnostic technologies and products.

Competitive Assessments

• Extensive strategic assessments of major suppliers and emerging market entrants, including their sales, product portfolios, marketing tactics, collaborative arrangements and new technologies/products in R&D.
• Companies developing and marketing molecular diagnostics products, by test and application.

Opportunities and Strategic Recommendations

• Specific new product development opportunities with potentially significant market appeal during the next five years.

Contents

I. Introduction
II. Major Product Development Opportunities
A. Instrumentation
B. Reagent Kits and Test Systems/Panels
C. Computers, Software and Automation
D. Auxiliary Products
III. Design Criteria for Decentralized Testing Products
IV. Alternative Market Penetration Strategies
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies for Decentralized Testing
Markets
V. Potential Market Entry Barriers and Risks
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
VI. Worldwide Market and Technology Review
A. DNA Sequencing

1. INTRODUCTION


2. SEQUENCING METHODS


3. AUTORADIOGRAPHY


4. THE HUMAN GENOME PROJECT


5. SEQUENCING AUTOMATION


6. IMAGE SCANNERS


7. FLUORESCENT DETECTION


8. GENE PROFILING


9. GENE EXPRESSION


10. POLYMORPHISM SCREENING


11. PROTEIN INTERACTION NETWORKS


B. DNA and RNA Probe Technologies

1. BASIC PRINCIPLES


2. PROBE PREPARATION


3. THE DNA PROBE TEST


4. TEST FORMATS


5. LABELING TECHNIQUES


6. AMPLIFICATION METHODS

C. Detection Technologies

1. RADIOACTIVE METHODS


2. NON-ISOTOPIC METHODS

D. Instrumentation
Review of latest analyzers from Abbott, Beckman Coulter/Danaher,
Becton Dickinson, bioMerieux, Bio-Rad, Cepheid, Hologic, Qiagen, Roche,
Siemens Healthineers, and others.
E. Biochips: Genosensors, Microarrays, and Labs-on-the-Chip
F. Pharmacogenomics
G. Major Applications

1. MICROBIOLOGY/INFECTIOUS DISEASES

a. Overview
b. Major Infectious Diseases
° AIDS: HIV/HIV-1/2/Combo, HIVAg/HIV NAT,
Western Blot, HTLV-I/II
° Adenovirus
° Aeromonas
° Anthrax/Bacillus Anthracis
° Arboviruses
° Babesiosis
° Bacillary Epithelioid Angiomatosis (BEA)
and Other Bartonella (Rochalimaea)
° Blastocystis Hominis
° Brucella
° Campylobacter
° Candida
° Chagas Disease

° Chancroid
° Chlamydia
° Clostridium Difficile
° Coronaviruses
° Coxsackieviruses
° Creutzfeldt-Jakob’s Disease
° Cryptosporidium Parvum
° Cyclospora Cayetanensis
° Cytomegalovirus
° Ebola Virus
° E. Coli
° EchoVirus
° Encephalitis
° Enteroviruses
° Epstein-Barr Virus
° Giardia Lamblia
° Gonorrhea
° Granuloma Inguinale
° Hantavirus
° Helicobacter Pylori
° Hepatitis: HAV NAT, HBV NAT, HBs Ag, HCV, HCV NAT, AntiHBc, Anti-HBs, Anti-HAV, Hepatitis Delta, HBc Ag, HBe Ag,
ALT/SGPT
° Herpes Simplex Virus
° Human Herpes Virus-6 (HHV-6)
° Influenza Viruses
° Legionella
° Lyme Disease
° Lymphogranuloma Venereum (LGV)
° Malaria
° Measles (Rubeola)
° Meningitis
° Microsporidium
° Mononucleosis
° Mumps
° Mycoplasma
° Papillomaviruses
° Parvovirus B19
° Pneumonia
° Polyomaviruses
° Pseudomonas Aeruginosa
° Rabies
° Respiratory Syncytial Virus (RSV)
° Rhinoviruses
° Rotavirus
° Rubella
° Salmonellosis

° Septicemia
° Shigellosis
° Staphylococcus Aureus
° Streptococci
° Syphilis
° Toxoplasmosis
° Trichomonas Vaginalis
° Tuberculosis
° Vibrio
° West Nile Virus
° Yersinia

2. CANCER TESTING

a. Overview
b. Major Cancer Types
* Prostate
* Lung
* Colon and Rectum
* Breast
* Skin
* Uterine
* Leukemia
* Oral
c. Oncogenes
The report provides review of both current and emerging oncogenes, including:
O Abl/abl-bcr
O AIB1
O BCL-2
O BRCA1
O CD44
O C-fos
O C-myb
O C-myc
O CYP17
O Erb-B
O HPC1
O N-myc
O P40
O P51
O P53
O PIK3CA
O PTI-1